2025 Hyper Recent •CC0 1.0 Universal

This work is dedicated to the public domain. No rights reserved.

Access Preprint From Server
June 5th, 2025
Version: 2
Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA 92037, USA.
cancer biology
biorxiv

Leveraging autophagy and pyrimidine metabolism to target pancreatic cancer

Dufresne, S.Open in Google Scholar•Kuna, R. S.Open in Google Scholar•Wong, K.Open in Google Scholar•Komarla, A.Open in Google Scholar•Rock, A.Open in Google Scholar•Rosada-Encarnacion, J.Open in Google Scholar•Shen, C.Open in Google Scholar•Mondal, P.Open in Google Scholar•Parham, L. R.Open in Google Scholar•Layng, F. I.Open in Google Scholaret al.

Autophagy inhibitors are promising compounds to treat pancreatic ductal adenocarcinoma (PDA) but their efficacy in patients is unclear, highlighting a need to understand mechanisms of resistance. We used a novel approach to uncover metabolic adaptations that bypass autophagy inhibition. Utilizing PDA cells with acquired resistance to different autophagy inhibitors, we found that severe autophagy depletion induces metabolic rewiring to sustain TCA intermediates and nucleotides for biosynthesis. Long-term autophagy inhibition results in altered pyruvate metabolism likely regulated by lower pyrimidine pools. Cells adapting to loss of autophagy preferentially salvage pyrimidines to replenish these pools instead of synthesizing them de novo. Exploiting this metabolic vulnerability, we found that acquired resistance to autophagy inhibition promotes increased salvage and therefore sensitivity to pyrimidine analogues, including gemcitabine and trifluridine/tipiracil leading to combinatory effects with autophagy inhibitors and pyrimidine analogs. These studies provide mechanistic insight defining how autophagy inhibition can be leveraged to treat pancreatic cancer.

Similar Papers

biorxiv
Fri Jun 06 2025
Astrocyte reprogramming drives tumor progression and chemotherapy resistance in agent-based models of breast cancer brain metastases
Breast cancer brain metastases (BCBM) affect nearly 90,000 patients annually in the United States and carry a significant risk of mortality. As metastatic lesions develop, the unique milieu of the brain microenvironment shapes disease progression and therapeutic response. Among resident brain cells, astrocytes are both the most common, and are increasingly recognized as key regulators of this proc...
Kaur, R.
•
Barker-Clarke, R.
•
Dhawan, A.
biorxiv
Fri Jun 06 2025
Lactate cannot replace glucose for maintaining the viability of mouse and human glioma cells
Objectives: Aerobic lactic acid fermentation (the \'\'Warburg effect\'\') is associated with OxPhos insufficiency and altered energy metabolism in most cancers. Whether lactate is a major fuel in cancer cells remains debated. This study investigated whether lactate could serve as a metabolic fuel in glioma cells and replace glucose to support viability. Methods: A bioluminescence ATP assay and cal...
Miller, E. Y.
•
Duraj, T.
•
Ta, N. L.
•
Lee, D. C.
...•
Seyfried, T. N.
biorxiv
Fri Jun 06 2025
Increasing Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival
Cancer progression involves loss of differentiation and acquisition of stem cell-like traits, broadly referred to as "stemness". Here, we test whether the level of stemness, assessed by a transcriptome-derived Stemness score, can quantitatively track prostate cancer (PCa) development, progression, therapy resistance, metastasis, plasticity, and patient survival. Integrative analysis of transcripto...
Liu, X.
•
Cortes, E.
•
Ji, Y.
•
Zhao, K.
...•
Tang, D. G.
biorxiv
Fri Jun 06 2025
BEHAV3D Tumor Profiler to map heterogeneous cancer cell behavior in the tumor microenvironment
Intravital microscopy (IVM) enables live imaging of animals at single-cell level, offering essential insights into cancer progression. This technique allows for the observation of single-cell behaviors within their natural 3D tissue environments, shedding light on how genetic and microenvironmental changes influence the complex dynamics of tumors. IVM generates highly complex datasets that often e...
Rios-Jimenez, E.
•
Zomer, A.
•
Collot, R.
•
Barrera Roman, M.
...•
Alieva, M.
biorxiv
Fri Jun 06 2025
Statin-dye conjugates for selective targeting of KRAS mutant cancer cells
Over 90% of pancreatic ductal adenocarcinoma (PDAC) patients involve KRAS mutations (KRASMUT), for which current treatment options are limited. Statins, commonly used to lower cholesterol, have demonstrated certain selective toxicity towards KRAS-transformed cells, prompting the question of whether statins could achieve selective uptake specifically in KRASMUT cells. To investigate this, we synthe...
Moon, H.-r.
•
Cai, Z.
•
Cho, B. K.
•
Chang, H.
...•
Ryu, J. H.
biorxiv
Fri Jun 06 2025
Modelling medulloblastoma pathogenesis and treatment in human cerebellar organoids.
Faithful genetically engineered in vivo models of medulloblastoma (MB) are currently available only for some molecular subgroups, in keeping with recent studies showing the unique role of human-specific progenitors in the development of G3 and G4 MB subgroups. We generated human cerebellar organoids (CbO) from expanded potential stem cells (EPSC) and characterised their epigenetic and transcriptom...
Willott, T. O.
•
Nicholson, J. G.
•
Xiao, Y.
•
Ogunbiyi, O. K.
...•
Marino, S.
biorxiv
Fri Jun 06 2025
Sequential Activation of Senescence and Apoptosis by ONG41008 Eliminated the Human Pancreatic Ductile Adenocarcinoma in nude mice and xenografted human lung cancer
Current therapeutic limitations associated with pancreatic ductal adenocarcinoma (PDAC) are still evident. We have found that ONG41008, the first human synthetic polyphenol, is able to eradicate PDAC in a nude mouse model. ONG41008 is known to potently attenuate human TGF-{beta} production, inducing both anti-fibrotic capacity and anticancer potential through senescence-coupled apoptosis (SCA). Th...
Youn, B.-S.
•
Kim, K.
•
Kim, Y.
biorxiv
Thu Jun 05 2025
Contrastive Learning-Enhanced Drug Metabolite Prediction Drives the Discovery of an Orally Bioavailable RSK4 Inhibitor for Esophageal Cancer
Drug metabolism liabilities are a major bottleneck in drug development, necessitating accurate metabolite prediction tools. While AI-driven methods have advanced, challenges remain in achieving high-precision, robustness, broad reaction coverage and seamless integration into the drug development workflow. To address this, we first constructed the most comprehensive human-specific drug metabolism d...
He, H.
•
Zhang, M.
•
Yang, X.
•
He, S.
...•
Li, S.
biorxiv
Thu Jun 05 2025
Inferring cell dynamics in stress-induced neuroblastoma cell cultures
Neuroblastoma is characterised by significant intratumoural heterogeneity which complicates treatments. Phenotypic plasticity, i.e., the ability of cells to alter their phenotype without genetic mutations, is a key factor contributing to this heterogeneity. In this study, we quantify cell actions and cell-to-cell interactions that lead to phenotypic adaptation in vitro under stress, specifically l...
Hafiichuk, K.
•
Hamis, S.
•
Karlsson, J.
•
Gisselsson, D.
•
Chattopadhyay, S.